TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Ankyra Therapeutics Commences Phase 1 Clinical Trial Dose Escalation Cohort for ANK-101, an Anchored Immune Medicine, Aimed at Solid Tumors with First Patient Dosed

Wednesday, March 06, 2024

Ankyra Therapeutics, a biotechnology company focusing on anchored immunotherapies for cancer treatment, has announced that the first patient has been dosed in the dose escalation cohort of a Phase 1 clinical trial evaluating ANK-101. This drug, intended to target tumors directly, is seen as a significant advancement in offering potential treatments with fewer adverse effects.

According to Dr. Howard L. Kaufman, President and CEO of Ankyra Therapeutics, this milestone is crucial in their mission to provide effective therapies with minimal side effects. ANK-101, an interleukin-12 (IL-12) cytokine anchored to aluminum hydroxide, is engineered for local delivery and retention within the tumor microenvironment, where it stimulates the recruitment and activation of immune cells. Preclinical studies have demonstrated promising results, showing increased immune cell infiltration into tumors without systemic toxicity.

The Phase 1 study is ongoing to evaluate the safety of ANK-101 and determine the recommended dosage for expansion in patients with various advanced solid tumors. Dr. Joe Elassal, Chief Medical Officer of Ankyra Therapeutics, highlighted the potential of ANK-101 to provide effective immunotherapy while minimizing adverse effects during treatment. The study will also assess pharmacokinetics, immunogenicity, and initial clinical activity.

Dr. Jong Chul Park, an investigator in the Phase 1 trial, emphasized the importance of patient well-being and the potential impact of ANK-101's novel delivery mechanism in oncology. ANK-101, composed of IL-12 linked to aluminum hydroxide, allows for localized delivery of IL-12 to the tumor site, activating anti-tumor immunity without systemic toxicity. It is being investigated for use alone and in combination with other therapies for advanced solid tumors.

In summary, ANK-101 represents a promising approach in cancer treatment, offering the potential for effective immunotherapy while minimizing side effects. This Phase 1 trial will provide valuable insights for future clinical development and identification of suitable indications for further studies.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement SummitHealthcare Innovation & Transformation Summit